2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2668

Real Time Sonoelastography in Primary Sjögren’s Syndrome Correlates with Morphological Ultrasonographic Features and Glandular Activity but Not with Glandular Fibrosis

Sjögren's Syndrome - Poster II: Clinical Science

9:00AM-11:00AM: Abstract Number: 2603

Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2595

Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2484

Real World Treat to Target Strategy in Rheumatoid Arthritis: Radiograph and MRI Outcomes in Three Cohorts with 18 Month Follow up

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2318

Real World Use of the Myositis Autoantibody Panel

Muscle Biology, Myositis and Myopathies - Poster II: Clinical

9:00AM-11:00AM: Abstract Number: 2247

REAL-Life Cost of UK Healthcare Resource for Patients with Rheumatoid Arthritis, Comparing High and Low/Remission Disease States

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2228

Real-World Cost of Treating Inadequate Responders to Anti-Tumor Necrosis Factor Therapy

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2523

Reasons for Provider Non-Adherence to a Treat to Target Strategy in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2335

Recent Changes of Radiological Findings and Patients’ Background of Rheumatoid Hip and Knee

Orthopedics, Low Back Pain and Rehabilitation - Poster

9:00AM-11:00AM: Abstract Number: 2221

Recognition of Secondary Fibromyalgia Using an Index of 3 Components of the Multi-Dimensional Health Assessment Questionnaire: 90% Agreement with ACR Criteria for Fibromyalgia

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

9:00AM-11:00AM: Abstract Number: 2510

Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2148

Recruitment of Circulating Monocytes By TNF/IL-6-Induced Expression of Vascular Cell Adhesion Molecule 1 (VCAM-1) Drives Valvular Inflammation in K/B/g7 Mice

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 2881

Reduced Hippocampal-Thalamic Fiber Tracts in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 2452

Reduced Ovarian Reserve in Young Juvenile Idiopathic Arthritis Patients

Reproductive Issues in Rheumatic Disorders - Poster

9:00AM-11:00AM: Abstract Number: 2542

Reducing the Dosage of Glucocorticoid to Zero Might Decrease Risk of Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].